How to evaluate emerging technologies in cervical canc

International Journal of Cancer
125, 2489-2496
DOI: 10.1002/ijc.24774

Citation Report

#	Article	IF	Citations
1	Comparison of Liquid-Based Cytology With Conventional Cytology for Detection of Cervical Cancer Precursors. JAMA - Journal of the American Medical Association, 2009, 302, 1757.	7.4	205
2	Trials comparing cytology with human papillomavirus screening. Lancet Oncology, The, 2009, 10, 935-936.	10.7	66
3	Performance of p16INK4a-cytology, HPV mRNA, and HPV DNA testing to identify high grade cervical dysplasia in women with abnormal screening results. Gynecologic Oncology, 2010, 119, 98-105.	1.4	59
4	Cervical Cytology Biobanking in Europe. International Journal of Biological Markers, 2010, 25, 117-125.	1.8	21
5	Optional screening strategies for cervical cancer using standalone tests and their combinations among low- and medium-income populations in Latin America and Eastern Europe. Journal of Medical Screening, 2010, 17, 195-203.	2.3	12
6	Commercially available assays for multiplex detection of alpha human papillomaviruses. Expert Review of Anti-Infective Therapy, 2010, 8, 1139-1162.	4.4	108
7	Comparison of the clinical performance of carcinogenic HPV typing of the Linear Array and PapillocheckÂ® HPV-screening assay. Journal of Clinical Virology, 2010, 47, 38-42.	3.1	26
8	Evaluation of the clinical performance of the Abbott RealTime High-Risk HPV for carcinogenic HPV detection. Journal of Clinical Virology, 2010, 48, 246-250.	3.1	20
9	Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China. Lancet Oncology, The, 2010, 11, 1160-1171.	10.7	129
10	HPV-based cervical-cancer screening in China. Lancet Oncology, The, 2010, 11, 1112-1113.	10.7	28
11	The interface of population-based cancer registries and biobanks in etiological and clinical research â€“ current and future perspectives. Acta OncolÃ³gica, 2010, 49, 1227-1234.	1.8	16
12	Human papillomavirus and cervical cancer: biomarkers for improved prevention efforts. Future Microbiology, 2011, 6, 1083-1098.	2.0	121
13	Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial. Lancet, The, 2011, 378, 1868-1873.	13.7	191
14	CIP2A expression is elevated in cervical cancer. Cancer Biomarkers, 2011, 8, 309-317.	1.7	27
15	Inhibition of the epidermal growth factor receptor by erlotinib prevents immortalization of human cervical cells by Human Papillomavirus type 16. Virology, 2011, 421, 19-27.	2.4	23
16	Comparison of different commercial methods for HPV detection in follow-up cytology after ASCUS/LSIL, prediction of CIN2â€“3 in follow up biopsies and spontaneous regression of CIN2â€“3. Gynecologic Oncology, 2011, 123, 278-283.	1.4	45
17	DNA Cytometry Testing for Cervical Cancer Screening: Approaches and Reporting Standards for New Technologies. Clinical Cancer Research, 2011, 17, 6971-6972.	7.0	3
18	Comparison of Clinical and Analytical Performance of the Abbott RealTime High Risk HPV Test to the Performance of Hybrid Capture 2 in Population-Based Cervical Cancer Screening. Journal of Clinical Microbiology, 2011, 49, 1721-1729.	3.9	66

#	Article	IF	Citations
19	Persistent Carcinoma in Cervical Cancer Screening: Non-Participation Is the Most Significant Cause. Acta Cytologica, 2011, 55, 433-437.	1.3	39
20	Human papillomavirus testing: the challenges of picking the right tools for the job. Expert Review of Obstetrics and Gynecology, 2011, 6, 643-653.	0.4	5
21	Genome-wide methylation profiling identifies hypermethylated biomarkers in high-grade cervical intraepithelial neoplasia. Epigenetics, 2012, 7, 1268-1278.	2.7	40
22	Inviting Patients to Read Doctors' Notes. Annals of Internal Medicine, 2012, 156, 608.	3.9	50
23	Screening for Cervical Cancer. Annals of Internal Medicine, 2012, 156, 604.	3.9	4
24	Defining Patient Complexity. Annals of Internal Medicine, 2012, 156, 607.	3.9	50
25	Defining Patient Complexity. Annals of Internal Medicine, 2012, 156, 606.	3.9	7
26	Human papillomavirus genotyping, human papillomavirus mRNA expression, and p16/Ki-67 cytology to detect anal cancer precursors in HIV-infected MSM. Aids, 2012, 26, 2185-2192.	2.2	70
27	Comparison of Seven Tests for High-Grade Cervical Intraepithelial Neoplasia in Women with Abnormal Smears: the Predictors 2 Study. Journal of Clinical Microbiology, 2012, 50, 1867-1873.	3.9	150
28	Estimation of disease prevalence, true positive rate, and false positive rate of two screening tests when disease verification is applied on only screen-positives: A hierarchical model using multi-center data. Cancer Epidemiology, 2012, 36, 153-160.	1.9	16
29	Claspin as a biomarker of human papillomavirus-related high grade lesions of uterine cervix. Journal of Translational Medicine, 2012, 10, 132.	4.4	18
30	Current guidelines for cervical cancer screening. Journal of the American Academy of Nurse Practitioners, 2012, 24, 417-424.	1.4	16
31	Nucleic Acid Tests for the Detection of Alpha Human Papillomaviruses. Vaccine, 2012, 30, F100-F106.	3.8	91
32	3q26 Amplification Is an Effective Negative Triage Test for LSIL: A Historical Prospective Study. PLoS ONE, 2012, 7, e39101.	2.5	10
33	Comparison of the AdvanSure Human Papillomavirus Screening Real-Time PCR, the Abbott RealTime High Risk Human Papillomavirus Test, and the Hybrid Capture Human Papillomavirus DNA Test for the Detection of Human Papillomavirus. Annals of Laboratory Medicine, 2012, 32, 201-205.	2.5	19
34	p16^{INK4a} immunocytochemistry versus human papillomavirus testing for triage of women with minor cytologic abnormalities. Cancer Cytopathology, 2012, 120, 294-307.	2.4	70
35	p16^{INK4a}â€"Is the future of cervical cancer screening rosy?. Cancer Cytopathology, 2012, 120, 291-293.	2.4	0
37	p16/Ki-67 dual staining in cervico-vaginal cytology: Correlation with histology, Human Papillomavirus detection and genotyping in women undergoing colposcopy. Gynecologic Oncology, 2012, 126, 198-202.	1.4	57

#	Article	IF	Citations
38	Screening trial of human papillomavirus for early detection of cervical cancer in Santiago, Chile. International Journal of Cancer, 2013, 132, 916-923.	5.1	37
39	HPV genotype distribution according to severity of cervical neoplasia using the digene HPV genotyping LQ test. Archives of Virology, 2013, 158, 1143-1149.	2.1	9
40	Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial. Journal of Cystic Fibrosis, 2013, 12, 147-153.	0.7	30
41	Increasing Adherence to Cervical Cancer Screening Guidelines. Journal for Nurse Practitioners, 2013, 9, 528-535.	0.8	5
42	A framework provided an outline toward the proper evaluation of potential screening strategies. Journal of Clinical Epidemiology, 2013, 66, 639-647.	5.0	20
43	Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions. The Cochrane Library, 2021, 2021, CD008054.	2.8	67
44	Vaccination and Screening in Cervical Cancer Control and Prevention. , 2013, , 1175-1189.		0
45	Triage of women with minor abnormal cervical cytology: Metaâ€analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 highâ€risk human papillomavirus types. Cancer Cytopathology, 2013, 121, 675-687.	2.4	36
46	Clinical Impact of the Analytical Specificity of the Hybrid Capture 2 Test: Data from the New Technologies for Cervical Cancer (NTCC) Study. Journal of Clinical Microbiology, 2013, 51, 2901-2907.	3.9	26
47	High-Content Imaging in Cervical Cancer Screening. Journal of Biomolecular Screening, 2013, 18, 135-142.	2.6	2
48	Diagnostic Tests for the Detection of Human Papillomavirus-associated Cervical Lesions. Current Pharmaceutical Design, 2013, 19, 1358-1370.	1.9	9
49	Molecular Diagnosis of Human Papillomavirus Infections. , 2013, , .		3
50	HPV Diagnosis in Vaccination Era. , 2013, , .		0
51	Clinical application of DNA ploidy to cervical cancer screening: A review. World Journal of Clinical Oncology, 2014, 5, 931.	2.3	34
52	Performance of Self-Collected Cervical Samples in Screening for Future Precancer Using Human Papillomavirus DNA Testing. Journal of the National Cancer Institute, 2014, 107, dju400-dju400.	6.3	24
53	Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions. Nature Reviews Cancer, 2014, 14, 395-405.	28.4	295
54	Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncology, The, 2014, 15, 172-183.	10.7	508
55	Reply to triage of women with minor abnormal cervical cytology: Metaâ€analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 highâ€risk human papillomavirus types. Cancer Cytopathology, 2014, 122, 77-78.	2.4	0

#	Article	IF	Citations
56	Effectiveness of two strategies to follow-up ASC-US and LSIL screening results in The Netherlands using repeat cytology with or without additional hrHPV testing: a retrospective cohort study. Cancer Causes and Control, 2014, 25, 1141-1149.	1.8	9
57	Role of E6/E7 mRNA test in the diagnostic algorithm of HPV-positive patients showing ASCUS and LSIL: clinical and economic implications in a publicly financed healthcare system. Expert Review of Molecular Diagnostics, 2015, 15, 137-150.	3.1	13
58	The predictive value of human papillomavirus testing for the outcome of patients conservatively treated for stage IA squamous cell cervical carcinoma. Journal of Clinical Virology, 2015, 70, 53-57.	3.1	8
59	Prevalence of human papillomavirus infection and genotyping for population-based cervical screening in developed regions in China. Oncotarget, 2016, 7, 62411-62424.	1.8	19
60	Clinical validation of hrHPV testing on vaginal and urine self-samples in primary cervical screening (cross-sectional results from the Papillomavirus Dumfries and Gallowayâ€"PaVDaG study). BMJ Open, 2016, 6, e010660.	1.9	64
61	Biomarkers for Cervical Cancer Prevention Programs: The Long and Winding Road From Discovery to Clinical Use. Journal of Lower Genital Tract Disease, 2016, 20, 191-194.	1.9	7
62	Commercially available molecular tests for human papillomaviruses (HPV): 2015 update. Journal of Clinical Virology, 2016, 76, S3-S13.	3.1	105
63	Triage of HPV positive women in cervical cancer screening. Journal of Clinical Virology, 2016, 76, S49-S55.	3.1	236
64	VALGENT: A protocol for clinical validation of human papillomavirus assays. Journal of Clinical Virology, 2016, 76, S14-S21.	3.1	123
65	Molecular tests potentially improving HPV screening and genotyping for cervical cancer prevention. Expert Review of Molecular Diagnostics, 2017, 17, 379-391.	3.1	55
66	Interobserver reproducibility of cytologic p16^{INK4a}/Kiâ€67 dual immunostaining in human papillomavirusâ€positive women. Cancer Cytopathology, 2017, 125, 212-220.	2.4	25
67	Cytology versus HPV testing for cervical cancer screening in the general population. The Cochrane Library, 2017, 8, CD008587.	2.8	189
68	First-void urine: A potential biomarker source for triage of high-risk human papillomavirus infected women. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2017, 216, 1-11.	1.1	27
69	The Value of a Novel Panel of Cervical Cancer Biomarkers for Triage of HPV Positive Patients and for Detecting Disease Progression. Pathology and Oncology Research, 2017, 23, 295-305.	1.9	10
70	Analytic and Diagnostic Performances of Human Papillomavirus E6/E7 mRNA Test on up-to 11-Year-Old Liquid-Based Cervical Samples. A Biobank-Based Longitudinal Study. International Journal of Molecular Sciences, 2017, 18, 1480.	4.1	9
71	Biospecimens and Biobanking in Global Health. Clinics in Laboratory Medicine, 2018, 38, 183-207.	1.4	16
72	ANOVA model for network meta-analysis of diagnostic test accuracy data. Statistical Methods in Medical Research, 2018, 27, 1766-1784.	1.5	63
73	Characterization of JAK2 V617F (1849 G ï¼ž T) Mutation in Cervical Cancer Related to Human Papillomavirus and Sexually Transmitted Infections. Journal of Cancer Prevention, 2018, 23, 82-86.	2.0	10

#	Article	IF	Citations
74	VALHUDES: A protocol for validation of human papillomavirus assays and collection devices for HPV testing on self-samples and urine samples. Journal of Clinical Virology, 2018, 107, 52-56.	3.1	72
75	Liquid-based cytology: do ancillary techniques enhance detection of epithelial abnormalities?. Archives of Gynecology and Obstetrics, 2018, 298, 159-169.	1.7	2
76	Performance of DNA methylation assays for detection of high-grade cervical intraepithelial neoplasia (CIN2+): a systematic review and meta-analysis. British Journal of Cancer, 2019, 121, 954-965.	6.4	76
77	Long-term CIN3+ risk of HPV positive women after triage with FAM19A4/miR124-2 methylation analysis. Gynecologic Oncology, 2019, 154, 368-373.	1.4	32
78	Cervical Cancer Screening: Comparison of Conventional Pap Smear Test, Liquid-Based Cytology, and Human Papillomavirus Testing as Stand-alone or Cotesting Strategies. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 474-484.	2.5	24
79	p16/Ki-67 co-expression associates high risk human papillomavirus persistence and cervical histopathology: a 3-year cohort study in China. Oncotarget, 2016, 7, 64810-64819.	1.8	17
80	Host chemokine signature as a biomarker for the detection of pre-cancerous cervical lesions. Oncotarget, 2018, 9, 18548-18558.	1.8	6
81	Diagnostic Accuracy of Conventional Cell Blocks Along with p16INK4 and Ki67 Biomarkers as Triage Tests in Resource-poor Organized Cervical Cancer Screening Programs. Asian Pacific Journal of Cancer Prevention, 2019, 20, 917-923.	1.2	4
82	Direct bisulphite conversion of cervical samples for DNA methylation analysis. Epigenetics, 2022, 17, 1173-1179.	2.7	6
83	Screening for Cervical Cancer. Annals of Internal Medicine, 2012, 156, 605.	3.9	6
84	Sample Preparation and Profiling: Biomarker Discovery in Body Fluids by Proteomics. RSC Drug Discovery Series, 2013, , 113-135.	0.3	0
85	Filogenia y oncogÃ©nesis del virus del papiloma humano: una aproximaciÃ³n translacional al descubrimiento de biomarcadores para la detecciÃ³n de lesiones precancerosas de cÃ©rvix. Revista De La Academia Colombiana De Ciencias Exactas, Fisicas Y Naturales, 2019, 43, 351-365.	0.2	1
86	The effect of p16/Ki-67 and p16/mcm2 on the detection of cervical intraepithelial neoplasia: a prospective study from China. International Journal of Clinical and Experimental Pathology, 2018, 11, 4101-4108.	0.5	1
87	Metaâ€analysis of agreement/concordance statistics in studies comparing selfâ€vs clinicianâ€collected samples for <scp>HPV</scp> testing in cervical cancer screening. International Journal of Cancer, 2022, 151, 308-312.	5.1	31
88	Comparative performance of the human papillomavirus test and cytology for primary screening for highâ€grade cervical intraepithelial neoplasia at the population level. International Journal of Cancer, 2022, 150, 1422-1430.	5.1	4
89	Validation of BD Onclarity HPV Assay on Vaginal Self-Samples versus Cervical Samples Using the VALHUDES Protocol. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 2177-2184.	2.5	11
90	HPV Testing and its Role in Cervical Cancer Screening. Clinical Obstetrics and Gynecology, 2023, 66, 448-469.	1.1	0
91	Significance of diagnostic of hpv testing and cytoscopic studies in the aspect of gynecological screening detecting cervical pathology in women. BIO Web of Conferences, 2023, 65, 05006.	0.2	0